NASDAQ:CYTK - Cytokinetics Stock Price, Forecast & News

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics, Inc. (NASDAQ:CYTK) released its quarterly earnings data on Thursday, October, 31st. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.06. The biopharmaceutical company earned $6.06 million during the quarter, compared to the consensus estimate of $7.80 million. View Cytokinetics' Earnings History.

Cytokinetics is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Cytokinetics.

6 analysts have issued 12-month target prices for Cytokinetics' shares. Their forecasts range from $16.00 to $26.00. On average, they expect Cytokinetics' share price to reach $21.50 in the next twelve months. This suggests a possible upside of 44.8% from the stock's current price. View Analyst Price Targets for Cytokinetics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytokinetics.

News stories about CYTK stock have been trending neutral on Sunday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cytokinetics earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Cytokinetics.

Cytokinetics saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 8,470,000 shares, a decline of 9.9% from the January 15th total of 9,400,000 shares. Based on an average trading volume of 913,000 shares, the short-interest ratio is currently 9.3 days. Approximately 15.7% of the company's stock are short sold. View Cytokinetics' Current Options Chain.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Geron (GERN), TG Therapeutics (TGTX) and Progenics Pharmaceuticals (PGNX).

Cytokinetics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (12.20%), Driehaus Capital Management LLC (5.14%), Point72 Asset Management L.P. (5.13%), State Street Corp (4.30%), FMR LLC (3.02%) and Bank of New York Mellon Corp (1.08%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum and Value Fund L P Biotechnology. View Institutional Ownership Trends for Cytokinetics.

CYTK stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., UBS Group AG, Pinnacle Associates Ltd., South Dakota Investment Council, Arizona State Retirement System, Chicago Equity Partners LLC, Credit Suisse AG and Barclays PLC. Company insiders that have sold Cytokinetics company stock in the last year include Fady Ibraham Malik and Robert I Blum. View Insider Buying and Selling for Cytokinetics.

CYTK stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Point72 Asset Management L.P., Jennison Associates LLC, Jacobs Levy Equity Management Inc., Driehaus Capital Management LLC, State Street Corp, Goldman Sachs Group Inc. and Mirador Capital Partners LP. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for Cytokinetics.

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CYTK stock can currently be purchased for approximately $14.85.